Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month
08 nov. 2018 08h30 HE
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that, despite the...
Veritas Pharma Establishes New Subsidiary in Puerto Rico, USA
07 mai 2018 03h10 HE
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce the establishment of new...
Veritas Pharma Provides Corporate Update on Q1 2018
21 févr. 2018 03h10 HE
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to provide an official corporate...
Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility
29 déc. 2017 03h05 HE
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has completed a prestudy...
Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain
20 nov. 2017 03h05 HE
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert...